European Ombudsman finds no maladministration in Commission’s transparency mechanisms regarding purchase of COVID-19 vaccines, but suggests certain improvements
The European Ombudsman has delivered a decision (in case 175/2021/DL) finding no maladministration in the way in which the European Commission ensures transparency in relation to the team responsible for negotiating ‘advanced purchase agreements’ (APAs) with pharmaceutical companies for vaccines against COVID-19.
The complainant, a Member of the European Parliament, had submitted a request to the European Commission for public access concerning (1) the APA negotiated and signed with AstraZeneca, and (2) the names of the persons negotiating on behalf of the EU Member States. In late January 2021, the Commission made public a redacted version of the APA with AstraZeneca. The Ombudsman welcomed these developments and consequently ope